Immune oncology in hepatocellular carcinoma—hype and hope
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference11 articles.
1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
2. HCC therapies—lessons learned;Worns;Nat Rev Gastroenterol Hepatol,2014
3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (resorce): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017
4. Global patterns of hepatocellular carcinoma management from diagnosis to death: the bridge study;Park;Liver Int,2015
5. Immunological landscape and immunotherapy of hepatocellular carcinoma;Prieto;Nat Rev Gastroenterol Hepatol,2015
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development;Development & Reproduction;2023-12
2. The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma;Advanced Science;2023-04-21
3. Engineered Apoptosis-Bioinspired Nanoparticles Initiate Immune Cascade for Cancer Immunotherapy of Malignant Ascites;ACS Applied Materials & Interfaces;2023-02-14
4. Disrupted BRCA1‐PALB2 interaction induces tumor immunosuppression and T‐lymphocyte infiltration in HCC through cGAS‐STING pathway;Hepatology;2022-02-15
5. Prognostic Value of HLA Class I in Patients with Hepatocellular Carcinoma;Clinical Laboratory;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3